Identifying the underlying cause key to successful treatment
A recent article published in American Academy of Hospice and Palliative Medicine provides an overview of approaches for treating intractable nausea and vomiting in the palliative care setting. Published by Cleveland Clinic palliative medicine specialist Kyle Neale, DO, the article explains that nausea and vomiting are best addressed using a mechanistic approach focused on uncovering the underlying cause of the patient’s symptoms.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
There are multiple culprits for nausea and vomiting, particularly in the palliative care and oncology populations, including chemotherapy, anxiety, constipation, delayed motility of the gastrointestinal tract and functional bowel disorder. Although a number of medications can be trialed to alleviate the patient’s symptoms, Dr. Neale says there is no one-size-fits-all approach. The key, he explains, is to properly diagnose and treat the underlying cause by incorporating medications of different classes when needed.
“For chemotherapy-related nausea and vomiting, we usually prescribe ondansetron or prochlorperazine; we may occasionally escalate to a longer-acting drug like olanzapine,” explains Dr. Neale, a staff physician in Taussig Cancer Institute. For patients with anticipatory anxiety, drugs like lorazepam can be used to manage panic or anxiety episodes. Metoclopramide can also be helpful for encouraging motility and mitigating nausea.”
Many of the drugs clinicians have historically used to treat nausea and vomiting were originally designed for other purposes, he adds.
“For example, metoclopramide was initially derived to encourage motility in patients with poorly controlled diabetes, but it’s actually a very effective nausea drug as well. Olanzapine is actually an antipsychotic; at lower doses, however, it can be highly effective for managing severe chemotherapy-induced nausea and vomiting.”
Dr. Neale emphasizes that when there are several reasons behind a patient’s symptoms, an appropriate therapeutic regimen should be prescribed based on each medication’s mechanism of action.
Advertisement
“We know that the neurotransmitters in the area of the brain that promote nausea and vomiting are affected by many common medicines, so potential overlap should be considered,” he says. “For example, olanzapine targets many different neurotransmitters – a nice benefit that enables us to cover a lot of bases when several different causes of nausea are suspected.”
“In most cases, nausea and vomiting can be well-controlled with medication, so providing relatively rapid relief is simply a matter of finding the right treatment,” explains Dr. Neale. In general, nausea and vomiting are managed for as long as the underlying cause is present, but patients rarely require ongoing treatment.
Although available drugs for treating nausea and vomiting are quite safe, Dr. Neale cautions that care must be taken when adding medications to the patient’s existing drug regimen.
“We’re cautious when combining some of these drugs because of their potential to cause irreversible neurologic interactions in the long-term,” he says. “As a result, we judiciously avoid prescribing treatments that trigger too much of a dopamine or serotonin response. We also have to be careful that a patient’s other medications – particularly antidepressants and other antiemetics – are not activating too many of those neurotransmitters.”
Patients who are interested in incorporating complementary therapies such as meditation, acupuncture and aromatherapy are encouraged to explore options available through the Cleveland Clinic Center for Functional Medicine.
Advertisement
Finally, Dr. Neale encourages patients to speak up if their nausea and vomiting persists. “If the first medication does not work, other options are available,” he says.
Advertisement
Advertisement
Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population
Care paths and research initiatives aim to answer unmet clinical needs
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour